Atara Biotherapeutics (NASDAQ:ATRA) Shares Cross Below 50 Day Moving Average of $0.73

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report)'s stock price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.73 and traded as low as $0.68. Atara Biotherapeutics shares last traded at $0.71, with a volume of 832,144 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com upgraded Atara Biotherapeutics from a "sell" rating to a "hold" rating in a report on Friday, April 5th.

Atara Biotherapeutics Stock Performance

The firm has a fifty day simple moving average of $0.73 and a 200-day simple moving average of $0.81. The company has a market capitalization of $82.56 million, a PE ratio of -0.26 and a beta of 0.69.

Institutional Investors Weigh In On Atara Biotherapeutics

Institutional investors have recently made changes to their positions in the company. Josh Arnold Investment Consultant LLC increased its holdings in shares of Atara Biotherapeutics by 17.6% in the 3rd quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company's stock valued at $300,000 after acquiring an additional 30,000 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of Atara Biotherapeutics by 53.0% in the 3rd quarter. Private Advisor Group LLC now owns 95,463 shares of the biotechnology company's stock valued at $141,000 after acquiring an additional 33,063 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at approximately $57,000. Redmile Group LLC increased its holdings in shares of Atara Biotherapeutics by 3.8% in the 3rd quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company's stock valued at $9,296,000 after acquiring an additional 232,690 shares during the last quarter. Finally, Staley Capital Advisers Inc. increased its holdings in shares of Atara Biotherapeutics by 33.3% in the 3rd quarter. Staley Capital Advisers Inc. now owns 1,000,000 shares of the biotechnology company's stock valued at $1,480,000 after acquiring an additional 250,000 shares during the last quarter. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.